References
- Björklund B, Björklund V. Antigenicity of pooled human malignant and normal tissues by cytoimmunological technique. Presence of an insoluble, heat-labile tumour antigen. Int Arch Allergy 1957; 10: 153–184
- Björklund B, Björklund V. Biochemische und morphologische Gundlagen von TPA: Fortschritte in Richtung auf einen allgemeinen Marker für aktive Tumouren durch monoklonale Kartierung. Tumourmarkersystem CEA-TPA. Grundlagen, Methodik, klinische Konkordanz, M. Lüthgens, G. Schlegel. Umour Diagnostik, Leonberg 1987; 14–29
- Rydlander L, Bergman T, Schöberl E, Ziegler E, Skern T, Steiner G, Björklund P, Einarsson R, Zetterberg A, Jornvall H. Isolation and characterization of tissue polypeptide antigen specific (TF'S), a protein molecule used in the follow-up of malignancies. 1994, Submitted
- Holmlund E. Validation of TPS Assays: IRMA-ELISA-EIA. J Tumor Marker Oncol 1993; 8: 122
- Ng JSY, Sturgeon C M, Seth J, Paterson G M, Roulston J E, Leonard RCF. Serological marker for metastatic breast cancer. Dis Markers 1993; 11: 217–223
- Van Dalen A. Is TPS able to assist in Decision Making in Breast Cancer?. Tumour Associated Antigen, Oncogenes, Receptors, Cytokines in tumour Diagnosis and Therapy at the Beginning of the Nineties, R. Klapdor, Munchen 1992; 86–89
- van Dalen A. TPS in breast cancer - A Comparative study with carcinoembryonic antigen and CA 15—3. Tumour Biol 1992; 13: 10–17
- van Dalen, van der Linde D L, Heering K J, Blusse, van Oudalblas A. How can treatment response be measured in breast cancer patients?. Anticancer Res 1993; 13: 1901–1904
- van Dalen A, Barak V, Cremaschi A, Gion M, Molina R, Namer M, Stieber P, Sturgeon C, Einarsson R. Treatment response in metastatic breast cancer. A multicenter study comparing UICC and tumour marker changes. 1994, Submitted for publication